Lineage Cell Therapeutics, Inc. Deferred Tax Liabilities, Net
Lineage Cell Therapeutics, Inc. (LCTX) had Deferred Tax Liabilities, Net of $273.00 thousand as of 2024-12-31, per its 10-K filed 2025-03-10.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net
us-gaap:DeferredTaxLiabilities · last filed 2025-03-10
- 2024-12-31: Deferred Tax Liabilities, Net $273.00K.
- 2023-12-31: Deferred Tax Liabilities, Net $273.00K.
- 2022-12-31: Deferred Tax Liabilities, Net $2.08M.
- 2021-12-31: Deferred Tax Liabilities, Net $2.08M.
| Period end | Deferred Tax Liabilities, Net |
|---|---|
| 2024-12-31 | $273.00K 10-K · filed 2025-03-10 |
| 2023-12-31 | $273.00K 10-K · filed 2025-03-10 |
| 2022-12-31 | $2.08M 10-K · filed 2024-03-07 |
| 2021-12-31 | $2.08M 10-K · filed 2023-03-09 |
| 2020-12-31 | $2.08M 10-K · filed 2022-03-10 |
| 2017-09-30 | $4.80M 10-Q · filed 2018-11-08 |
| 2017-03-31 | $3.90M 10-Q · filed 2018-05-10 |
| 2016-12-31 | $0.00 10-K · filed 2017-03-16 |
| 2015-12-31 | $0.00 10-K · filed 2017-03-16 |
| 2014-12-31 | $4.51M 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |